시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 정맥주사 철분 제제 시장 보고서(2025년)
Intravenous Iron Drugs Global Market Report 2025
상품코드 : 1751029
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,156,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,898,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,640,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

정맥주사 철분 제제 시장 규모는 향후 수 년간 급성장이 전망될 예정입니다. 발화, 약제 투여와 제제의 개선 등에 기인한다고 생각됩니다. 예측 기간 중에 예상되는 주요 동향으로서는 첨단 정맥 내 철분 치료법의 등장, 약물 개발의 상당한 진전, 보다 편리한 정맥 내 철분 치료 옵션으로의 전환, 전략적 제휴, 파트너십, 인수, 신규 약물전달 시스템의 혁신 등을 들 수 있습니다.

만성 신장 질환(CKD)의 이환율 증가는 정맥주사 철분 제제 시장의 상당한 성장을 이끌 것으로 예측됩니다. 과다한 기능이 손상되는 것을 특징으로 하는 진행성 질환입니다. 주사는 철 수준을 회복시키고 헤모글로빈 농도를 개선하고 신체의 산소 공급을 강화함으로써 CKD와 관련된 빈혈을 관리하는 데 중요한 역할을합니다. 2024년 6월 호주 보건복지연구소는 CKD 관련 사망률이 2021년에 4.2%, 2022년에 6.2% 증가했다고 보고했습니다. 2022년에만 호주에서 약 22,000명의 사망자가 발생했으며, 이는 전체 사망자의 11%에 해당합니다. 그 결과, CKD의 부담의 증대가, 정맥내 철요법에 대한 수요를 가속시키고 있습니다.

정맥주사 철분 제제 시장의 신흥 국가 기업은 안전성, 효능 및 환자 경험을 향상시키기 위해 첨단 정맥 내 철 보충 요법의 개발을 우선시하고 있습니다. 예를 들어, 2023년 6월, 일본의 다이이치 산쿄 주식회사는 미국 식품의약국(FDA)으로부터, 뉴욕 심장협 회심부전 Ⅱ/Ⅲ 성인에서 철 결핍증의 치료제로서 인젝터(카르복시말토스 철 주사제)가 승인되었다고 발표했습니다. 부족에 대처하기 위해 Injectafer의 사용을 뒷받침하는 것입니다. 신속한 철분 보급으로 알려진 Injectafer는 경구 요법을 대체하는 귀중한 선택이며 치료의 충동과 결과를 향상시킵니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Intravenous iron drugs are iron formulations administered directly into the bloodstream to treat iron deficiency and iron deficiency anemia, particularly in patients who cannot tolerate or do not respond well to oral iron supplements. These drugs quickly elevate iron levels, support hemoglobin production, and enhance oxygen transport in the body, helping to relieve symptoms such as fatigue and weakness.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary product types of intravenous iron drugs include iron dextran, iron sucrose, ferric carboxymaltose, and other formulations. Iron dextran is an injectable iron therapy used for rapid iron replenishment in patients with severe deficiencies where oral iron is ineffective or poorly tolerated. These drugs are used to treat various conditions, including chronic kidney disease, inflammatory bowel disease, cancer, and other disorders. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The intravenous iron drugs market research report is one of a series of new reports from The Business Research Company that provides intravenous iron drugs market statistics, including the intravenous iron drugs global market size, regional shares, competitors with the intravenous iron drugs market share, detailed intravenous iron drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the intravenous iron drugs. This intravenous iron drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The intravenous iron drugs market size has grown rapidly in recent years. It will grow from $3.44 billion in 2024 to $3.84 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth during the historic period can be attributed to the increasing prevalence of iron deficiency anemia, a rise in chronic diseases, growing healthcare expenditure, an aging population, and the rising incidence of target illnesses requiring intravenous iron therapy.

The intravenous iron drugs market size is expected to see rapid growth in the next few years. It will grow to $5.86 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth during the forecast period can be attributed to supportive government initiatives, ongoing research and development in the field of intravenous (IV) iron drugs, increasing demand for IV iron therapies, a rising number of R&D activities, and improvements in drug administration and formulation. Key trends expected in the forecast period include the emergence of advanced intravenous iron therapies, significant advancements in drug development, a shift toward more convenient IV iron treatment options, strategic collaborations, partnerships, and acquisitions, as well as innovations in novel drug delivery systems.

The growing incidence of chronic kidney disease (CKD) is expected to drive significant growth in the intravenous iron drugs market. CKD is a progressive condition characterized by the gradual decline of kidney function, impairing the body's ability to filter waste and excess fluids from the blood. This rising trend is largely attributed to the increasing prevalence of diabetes and hypertension two major contributors to kidney damage. Intravenous iron drugs play a crucial role in managing CKD-related anemia by restoring iron levels, improving hemoglobin concentrations, and enhancing oxygen delivery in the body. These benefits reduce reliance on erythropoiesis-stimulating agents and support better patient outcomes. For example, in June 2024, the Australian Institute of Health and Welfare reported that CKD-related mortality increased by 4.2% in 2021 and by 6.2% in 2022. In 2022 alone, CKD accounted for approximately 22,000 deaths in Australia, representing 11% of total fatalities. As a result, the growing burden of CKD is accelerating the demand for intravenous iron therapies.

Leading players in the intravenous iron drugs market are prioritizing the development of advanced intravenous (IV) iron replacement therapies to enhance safety, efficacy, and patient experiences. IV iron replacement therapy involves delivering iron directly into the bloodstream, making it an effective treatment for iron deficiency and anemia, particularly in patients who are unable to tolerate or absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited a Japan-based pharmaceutical innovator announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adults with New York Heart Association class II/III heart failure. This approval supports the use of Injectafer to improve exercise capacity and addresses iron deficiency in a key patient population. Known for its rapid iron repletion capabilities, Injectafer offers a valuable alternative to oral therapies, enhancing treatment adherence and outcomes.

In August 2022, CSL Limited, an Australia-based biotechnology company known for its focus on plasma therapies and specialty pharmaceuticals, acquired Vifor Pharma for an undisclosed sum. This strategic acquisition enhances CSL's capabilities in nephrology and iron deficiency management, significantly strengthening its portfolio in renal and cardiovascular care. Vifor Pharma AG, headquartered in Switzerland, is recognized globally for its expertise in iron deficiency treatments and nephrology-focused pharmaceuticals.

Major players in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy's Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the intravenous iron drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intravenous iron drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intravenous iron drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intravenous iron drugs market consists of sales of ferric gluconate, ferumoxytol, ferric derisomaltose, and sodium ferric gluconate. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intravenous Iron Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intravenous iron drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for intravenous iron drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intravenous iron drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Intravenous Iron Drugs Market Characteristics

3. Intravenous Iron Drugs Market Trends And Strategies

4. Intravenous Iron Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Intravenous Iron Drugs Growth Analysis And Strategic Analysis Framework

6. Intravenous Iron Drugs Market Segmentation

7. Intravenous Iron Drugs Market Regional And Country Analysis

8. Asia-Pacific Intravenous Iron Drugs Market

9. China Intravenous Iron Drugs Market

10. India Intravenous Iron Drugs Market

11. Japan Intravenous Iron Drugs Market

12. Australia Intravenous Iron Drugs Market

13. Indonesia Intravenous Iron Drugs Market

14. South Korea Intravenous Iron Drugs Market

15. Western Europe Intravenous Iron Drugs Market

16. UK Intravenous Iron Drugs Market

17. Germany Intravenous Iron Drugs Market

18. France Intravenous Iron Drugs Market

19. Italy Intravenous Iron Drugs Market

20. Spain Intravenous Iron Drugs Market

21. Eastern Europe Intravenous Iron Drugs Market

22. Russia Intravenous Iron Drugs Market

23. North America Intravenous Iron Drugs Market

24. USA Intravenous Iron Drugs Market

25. Canada Intravenous Iron Drugs Market

26. South America Intravenous Iron Drugs Market

27. Brazil Intravenous Iron Drugs Market

28. Middle East Intravenous Iron Drugs Market

29. Africa Intravenous Iron Drugs Market

30. Intravenous Iron Drugs Market Competitive Landscape And Company Profiles

31. Intravenous Iron Drugs Market Other Major And Innovative Companies

32. Global Intravenous Iron Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intravenous Iron Drugs Market

34. Recent Developments In The Intravenous Iron Drugs Market

35. Intravenous Iron Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기